Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2020-07-02 Capital/Financing Update
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Vicore Pharma avser att genomföra en riktad nyemission av aktier
Capital/Financing Update Classification · 99% confidence The document is a press release from Vicore Pharma Holding AB announcing its intention to conduct a 'riktad nyemission av aktier' (directed new share issue) to raise approximately 160 million SEK. It details the use of proceeds (financing pivotal studies, development programs), the process (accelerated bookbuilding), and involvement of financial advisors (DNB Markets, Pareto Securities, Zonda Partners). This clearly relates to fundraising, financing activities, and capital structure changes. This aligns directly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2020-07-02 Swedish
Vicore Pharma intends to carry out a directed share issue
Capital/Financing Update Classification · 98% confidence The document is a press release announcing Vicore Pharma's intention to execute a 'directed share issue' to raise capital (SEK 160 million). It details the purpose of the funds (financing pivotal studies, preclinical development) and the mechanism (accelerated bookbuilding, deviation from preferential rights). This activity directly relates to fundraising, capital structure changes, and the issuance of new shares. The most fitting category is 'Capital/Financing Update' (CAP). While it involves shares, it is an announcement of a financing event rather than a general share issue (SHA) or a transaction in own shares (POS), as the primary focus is the capital raise itself. It is not a formal regulatory filing like a 10-K or an ER, but a specific corporate action announcement.
2020-07-02 English
Kommuniké från årsstämma i Vicore Pharma Holding AB (publ)
AGM Information Classification · 99% confidence The document is titled "Kommuniké från årsstämma i Vicore Pharma Holding AB (publ)" which translates to "Communication from the Annual General Meeting (AGM) in Vicore Pharma Holding AB (publ)". The text details decisions made at the AGM on May 20, 2020, including the approval of 2019 accounts, board elections, remuneration guidelines, and authorization for share issues. This content directly corresponds to the materials presented or decided upon during an Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). The document length is relatively short (4775 chars) and serves as a summary/communication of the meeting outcomes, fitting the scope of AGM-R rather than a full regulatory filing like 10-K or a general announcement (RPA/RNS).
2020-05-20 Swedish
Bulletin from the Annual General Meeting of Vicore Pharma Holding AB (publ)
AGM Information Classification · 100% confidence The document explicitly states it is a 'Bulletin from the Annual General Meeting of Vicore Pharma Holding AB (publ)' and details the resolutions passed at the AGM on May 20, 2020. Key items include the adoption of financial statements, election of board members, approval of remuneration guidelines, authorization to issue new shares, and implementation of an incentive program. These are all core components of an AGM outcome report. Therefore, the classification is AGM-R (AGM Information). The document length (5397 chars) is substantial enough to be the report itself, not just an announcement of one.
2020-05-20 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Vicore Pharma Holding AB for the period 1 January to 31 March 2020. It contains comprehensive financial statements, including a consolidated income statement, balance sheet, cash flow analysis, and management commentary (VD-ord). It is not a mere announcement or certification, but the full quarterly report itself, fitting the definition of an Interim/Quarterly Report (IR). Q1 2020
2020-05-05 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report Jan 1 - Mar 31, 2020' for Vicore Pharma Holding AB. It contains a table of contents, CEO comments, business focus areas, project overviews, and detailed financial statements (Group and Parent company) for the first quarter of 2020. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2020
2020-05-05 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.